School of Kinesiology, University of British Columbia, Vancouver, British Columbia, Canada.
J Neurotrauma. 2012 Mar 20;29(5):865-79. doi: 10.1089/neu.2011.2052. Epub 2012 Feb 29.
Studies of spinalized animals indicate that some pharmacological agents may act on receptors in the spinal cord, helping to produce coordinated locomotor movement. Other drugs may help to ameliorate the neuropathological changes resulting from spinal cord injury (SCI), such as spasticity or demyelination, to improve walking. The purpose of this study was to systematically review the effects of pharmacological agents on gait in people with SCI. A keyword literature search of articles that evaluated the effects of drugs on walking after SCI was performed using the databases MEDLINE/PubMed, CINAHL, EMBASE, PsycINFO, and hand searching. Two reviewers independently evaluated each study, using the Physiotherapy Evidence Database (PEDro) tool for randomized clinical trials (RCTs), and the modified Downs & Black scale for all other studies. Results were tabulated and levels of evidence were assigned. Eleven studies met the inclusion criteria. One RCT provided Level 1 evidence that GM-1 ganglioside in combination with physical therapy improved motor scores, walking velocity, and distance better than placebo and physical therapy in persons with incomplete SCI. Multiple studies (levels of evidence 1-5) showed that clonidine and cyproheptadine may improve locomotor function and walking speed in severely impaired individuals with incomplete SCI. Gains in walking speed associated with GM-1, cyproheptadine, and clonidine are low compared to those seen with locomotor training. There was also Level 1 evidence that 4-aminopyridine and L-dopa were no better than placebo in helping to improve gait. Two Level 5 studies showed that baclofen had little to no effect on improving walking in persons with incomplete SCI. There is limited evidence that pharmacological agents tested so far would facilitate the recovery of walking after SCI. More studies are needed to better understand the effects of drugs combined with gait training on walking outcomes in people with SCI.
对脊髓切断动物的研究表明,一些药理学药物可能作用于脊髓中的受体,有助于产生协调的运动。其他药物可能有助于改善脊髓损伤(SCI)引起的神经病理学变化,如痉挛或脱髓鞘,以改善行走。本研究的目的是系统地回顾药理学药物对 SCI 患者步态的影响。使用 MEDLINE/PubMed、CINAHL、EMBASE、PsycINFO 数据库和手工搜索对评估药物对 SCI 后行走影响的文章进行了关键词文献搜索。两名审查员使用物理治疗证据数据库(PEDro)工具对随机临床试验(RCT)进行了独立评估,对所有其他研究使用了改良的 Downs 和 Black 量表进行评估。结果进行了制表并分配了证据水平。有 11 项研究符合纳入标准。一项 RCT 提供了 1 级证据,表明 GM-1 神经节苷脂与物理疗法联合使用在不完全性 SCI 患者中的运动评分、行走速度和距离方面优于安慰剂和物理疗法。多项研究(证据水平 1-5)表明,可乐定和赛庚啶可能改善严重受损的不完全性 SCI 患者的运动功能和行走速度。与运动训练相比,GM-1、赛庚啶和可乐定所带来的行走速度提高幅度较低。也有 1 级证据表明,4-氨基吡啶和左旋多巴在帮助改善步态方面并不优于安慰剂。两项 5 级研究表明,巴氯芬对改善不完全性 SCI 患者的行走几乎没有影响。有有限的证据表明,迄今为止测试的药理学药物可能有助于 SCI 后行走的恢复。需要更多的研究来更好地了解药物与步态训练相结合对 SCI 患者行走结果的影响。